Top Markets
#1 Black Phoenix Black Phoenix +829.97%
#2 pipedog pipedog +41.42%
#3 PondCoin PondCoin +34.34%
#4 Bless Bless +32.22%
#5 FGRS (Figure Tokenized Stock) FGRS (Figure Tokenized Stock) +28.74%
#6 SAFEcoin SAFEcoin +26.51%
#7 Beam Beam +24.69%
#8 Magma Finance Magma Finance +19.36%
#9 Seeker Seeker +19.26%
#10 Not in Employment, Education, or Training Not in Employment, Education, or Training +16.16%
Coin of the day
Black Phoenix Black Phoenix
Settings
Language
ENGLISH
Currency
USD
Theme
Shenzhen Hepalink Pharmaceutical Group Co., Ltd. Shenzhen Hepalink Pharmaceutical Group Co., Ltd.

Shenzhen Hepalink Pharmaceutical Group Co., Ltd.

002399
Rank in Stocks #6665
Shenzhen Hepalink Pharmaceutical Group Co., Ltd. is an international... Shenzhen Hepalink Pharmaceutical Group Co., Ltd. is an international pharmaceutical enterprise specializing in the production and commercialization of medicinal products. Its operations span Hong Kong, the United States, Europe, Mainland China, and numerous other global markets. The company's business activities are structured into four primary segments: Finished Dose Pharmaceutical Products, Active Pharmaceutical Ingredients (API), Contract Development and Manufacturing Organization (CDMO), and an 'Others' category. Within its product portfolio, key offerings include finished dose pharmaceuticals, notably enoxaparin sodium injection. Its API division supplies critical ingredients such as heparin sodium API and enoxaparin sodium API, alongside other compounds like pancreatin API. Beyond core products, Hepalink provides a suite of services encompassing research and development, manufacturing, quality management, and program management. This also extends to the creation and production of recombinant pharmaceutical products, essential non-viral vectors, intermediates for gene therapy, and naturally derived pharmaceutical compounds. The group further diversifies its operations into areas such as property management, investment management and consulting, and equity and venture capital. It also engages in biopharmaceutical technology development and consulting, alongside the research, development, and production of biopharmaceuticals. Additional revenue streams include the production and sale of heparin sodium, various pharmaceutical-related service provisions, and the trading of medical and biopharmaceutical products. Established in 1998, the company is headquartered in Shenzhen, People's Republic of China. It adopted its current name, Shenzhen Hepalink Pharmaceutical Group Co., Ltd., in February 2017, having previously operated as Shenzhen Hepalink Pharmaceutical Co.,Ltd.
Share Price
$1.54
Market Cap
$1.92B
Change (1 day)
1.92%
Change (1 year)
-14.55%
Country
CN
Trade Shenzhen Hepalink Pharmaceutical Group Co., Ltd. (002399)

Category

Healthcare
Revenue for Shenzhen Hepalink Pharmaceutical Group Co., Ltd. (002399)
Revenue in Aug 2026 TTM: 0
According to Shenzhen Hepalink Pharmaceutical Group Co., Ltd. latest financial reports the company's current revenue (TTM) is 0. In 2026 the company made a revenue of 0 equal to the revenue in the year 2026 that was 0. The revenue is the total amount of income that a company generates by the sale of goods or services. Unlike with the earnings no expenses are subtracted.
Revenue history for Shenzhen Hepalink Pharmaceutical Group Co., Ltd. from 2026 to 2026
Revenue at the end of each year
Year Revenue Change
Not enough data for the provided dates.
Revenue for similar companies or competitors
Company Revenue Revenue Difference Country
MERCK Kommanditgesellschaft auf Aktien MERCK Kommanditgesellschaft auf Aktien
MERCK Kommanditgesellschaft auf Aktien
MER.SW
 - -
DE
Merck KGaA Merck KGaA
Merck KGaA
MRK.DE
 - -
DE
Takeda Pharmaceutical Company Limited Takeda Pharmaceutical Company Limited
Takeda Pharmaceutical Company Limited
4502.T
 - -
JP
Galderma Group AG Galderma Group AG
Galderma Group AG
GALD.SW
 - -
CH
Sun Pharmaceutical Industries Limited Sun Pharmaceutical Industries Limited
Sun Pharmaceutical Industries Limited
SUNPHARMA.NS
 $6.61B -
IN